Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Panthera Resources PLC (PAT.L) Income Statement Analysis – Financial Results
- SOMAR Corporation (8152.T) Income Statement Analysis – Financial Results
- Vishnu Prakash R Punglia Limited (VPRPL.NS) Income Statement Analysis – Financial Results
- DAE YOUNG Packaging.Co., Ltd. (014160.KS) Income Statement Analysis – Financial Results
- China Quanjude(Group) Co.,Ltd. (002186.SZ) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CALT)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 802.88M | 229.35M | 874.00K | 184.83M | 0.00 | 0.00 | 497.00K | 478.00K |
| Cost of Revenue | 77.06M | 15.20M | 0.00 | 0.00 | 0.00 | 51.00K | 51.00K | 56.52M | 51.39M |
| Gross Profit | 1.13B | 787.68M | 229.35M | 874.00K | 184.83M | -51.00K | -51.00K | -56.02M | -50.91M |
| Gross Profit Ratio | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Research & Development | 499.54M | 414.75M | 357.49M | 241.37M | 149.83M | 99.26M | 384.00K | 40.28M | 36.89M |
| General & Administrative | 332.99M | 259.47M | 210.63M | 102.76M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Selling & Marketing | 727.74M | 515.19M | 179.60M | 38.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01B | 774.66M | 390.23M | 141.72M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Other Expenses | 0.00 | 20.21M | 6.09M | 0.00 | 0.00 | 51.00K | 51.00K | 112.00K | 111.00K |
| Operating Expenses | 1.51B | 1.21B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Cost & Expenses | 1.59B | 1.22B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Interest Income | 29.10M | 50.20M | 102.00K | 547.00K | 926.00K | 6.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 73.20M | 12.53M | 7.11M | 393.00K | 325.00K | 8.00K | 2.24M | 1.01M | 9.00K |
| Depreciation & Amortization | 16.59M | 12.91M | 34.43M | 2.82M | 1.82M | 51.00K | 51.00K | 112.00K | 111.00K |
| EBITDA | -367.80M | -388.82M | -483.94M | -379.40M | -25.13M | -133.14M | -84.60M | -56.40M | -51.28M |
| EBITDA Ratio | -30.48% | -52.55% | -228.67% | -43,346.80% | -13.60% | 0.00% | 0.00% | -11,348.69% | -10,727.62% |
| Operating Income | -384.40M | -421.94M | -524.46M | -379.72M | -28.02M | -132.48M | -84.51M | -56.02M | -50.91M |
| Operating Income Ratio | -31.85% | -52.55% | -228.67% | -43,446.22% | -15.16% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Total Other Income/Expenses | -72.62M | 5.39M | 9.47M | -53.93M | -4.48M | 1.15M | -2.29M | -395.00K | 375.00K |
| Income Before Tax | -457.02M | -409.42M | -513.37M | -436.15M | -32.50M | -132.05M | -86.79M | -56.91M | -51.01M |
| Income Before Tax Ratio | -37.87% | -50.99% | -223.84% | -49,902.86% | -17.58% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| Income Tax Expense | 9.17M | 2.85M | -3.84M | 360.00K | 77.00K | 441.00K | 2.24M | 1.01M | 9.00K |
| Net Income | -466.19M | -412.27M | -509.54M | -436.51M | -32.58M | -132.05M | -86.79M | -56.91M | -51.01M |
| Net Income Ratio | -38.63% | -51.35% | -222.17% | -49,944.05% | -17.63% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| EPS | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| EPS Diluted | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| Weighted Avg Shares Out | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
| Weighted Avg Shares Out (Dil) | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
Launch of Phase 3 clinical trial with Nefecon in Japan
STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the...
Calliditas provides setanaxib patent update
STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM , June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:...
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALT
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate MODN, CALT
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT
NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
STOCKHOLM , May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the...
Calliditas Therapeutics' stock surges after $1.1 billion takeover bid
Calliditas Therapeutics AB's American depositary receipts CALT, -1.45% jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from Japanese conglomerate Asahi Kasei.
Source: https://incomestatements.info
Category: Stock Reports